Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap.

[1]  B. Chi,et al.  Ending the evidence gap for pregnancy, HIV and co‐infections: ethics guidance from the PHASES project , 2021, Journal of the International AIDS Society.

[2]  R. Stalter,et al.  Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection , 2021, Expert opinion on drug safety.

[3]  L. Myer,et al.  Early pre-exposure prophylaxis (PrEP) discontinuation among pregnant and postpartum women: Implications for maternal PrEP roll out in South Africa , 2021, medRxiv.

[4]  J. Currier,et al.  Accelerating drug discovery for pregnant and lactating women living with HIV , 2021, Journal of the International AIDS Society.

[5]  Ashley J. Mayo,et al.  Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. , 2021, The lancet. HIV.

[6]  L. Bekker,et al.  Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. , 2021, The lancet. HIV.

[7]  B. Chi,et al.  Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Delany-Moretlwe,et al.  Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020 , 2020, Southern African journal of HIV medicine.

[9]  Gabrielle E. O'Malley,et al.  Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation from a PrEP implementation program. , 2020, Journal of acquired immune deficiency syndromes.

[10]  L. Myer,et al.  'I had made the decision, and no one was going to stop me': Facilitators of PrEP adherence during pregnancy and postpartum in Cape Town, South Africa , 2020, medRxiv.

[11]  B. Chi,et al.  Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. , 2020, The lancet. HIV.

[12]  G. John-Stewart,et al.  Importance of Inclusion of Pregnant and Breastfeeding Women in COVID-19 Therapeutic Trials , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  B. Chi,et al.  Incident HIV among pregnant and breast-feeding women in sub-Saharan Africa: a systematic review and meta-analysis. , 2020, AIDS.

[14]  K. Dooley,et al.  Tenofovir alafenamide use in pregnant and lactating women living with HIV , 2020, Expert opinion on drug metabolism & toxicology.

[15]  B. Chi,et al.  Emerging evidence from a systematic review of safety of pre‐exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading? , 2020, Journal of the International AIDS Society.

[16]  R. Karron,et al.  Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response☆ , 2021, Vaccine.

[17]  J. Baeten,et al.  Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. , 2019, The lancet. HIV.

[18]  A. Lyerly.  Dolutegravir: advancing ethical research in pregnancy , 2019, The Lancet.

[19]  J. Baeten,et al.  Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. , 2019, AIDS.

[20]  R. Walensky,et al.  Where Were the Women? Gender Parity in Clinical Trials. , 2019, The New England journal of medicine.

[21]  B. Chi,et al.  The landscape for HIV pre-exposure prophylaxis during pregnancy and breastfeeding in Malawi and Zambia: A qualitative study , 2019, PloS one.

[22]  M. Peet,et al.  Topical Inserts: A Versatile Delivery Form for HIV Prevention , 2019, Pharmaceutics.

[23]  S. Lockman,et al.  Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. , 2019, The New England journal of medicine.

[24]  J. Billingsley,et al.  Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial. , 2019, The Lancet HIV.

[25]  L. Myer,et al.  Prevalence and correlates of sexually transmitted infections in pregnancy in HIV-infected and- uninfected women in Cape Town, South Africa , 2019, PloS one.

[26]  A. Slogrove,et al.  Methodological Considerations in Evaluating Pregnancy Outcomes in Women Living With HIV. , 2019, Journal of acquired immune deficiency syndromes.

[27]  I. Hoffman,et al.  Women’s views about contraception requirements for biomedical research participation , 2019, PloS one.

[28]  J. V. Delden,et al.  How the CIOMS guidelines contribute to fair inclusion of pregnant women in research. , 2019 .

[29]  C. Deal,et al.  Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial. , 2019, The Journal of infectious diseases.

[30]  K. Bunge,et al.  Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring , 2019, Antimicrobial Agents and Chemotherapy.

[31]  Ashley J. Mayo,et al.  Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings , 2018, Clinical Infectious Diseases.

[32]  J. Baeten,et al.  Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy , 2018, Journal of acquired immune deficiency syndromes.

[33]  J. Baeten,et al.  Lessons from PrEP: A Qualitative Study Investigating How Clinical and Policy Experts Weigh Ethics and Evidence When Evaluating Preventive Medications for Use in Pregnant and Breastfeeding Women , 2018, AIDS and Behavior.

[34]  R. Heffron,et al.  Global and national guidance for the use of pre-exposure prophylaxis during peri-conception, pregnancy and breastfeeding. , 2018, Sexual health.

[35]  A. Rana,et al.  Evaluating outcomes of mother–infant pairs using dolutegravir for HIV treatment during pregnancy , 2018, AIDS.

[36]  L. Meyn,et al.  FAME‐04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir , 2018, Journal of the International AIDS Society.

[37]  C. Thorne,et al.  HIV treatment in pregnancy. , 2018, The lancet. HIV.

[38]  J. Baeten,et al.  Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners , 2018, The Journal of infectious diseases.

[39]  L. Myer,et al.  Sexual risk during pregnancy and postpartum periods among HIV-infected and –uninfected South African women: Implications for primary and secondary HIV prevention interventions , 2018, PloS one.

[40]  J. Baeten,et al.  Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. , 2018, AIDS.

[41]  M. Little,et al.  Research with pregnant women: a call to action , 2017, Reproductive Health.

[42]  B. Haire,et al.  Undue inducement, or unfair exclusion: considering a case study of pregnancy in an HIV prevention trial , 2017, Journal of Medical Ethics.

[43]  L. Mofenson,et al.  Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding , 2017, AIDS.

[44]  A. van der Straten,et al.  Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. , 2017, AIDS Research and Human Retroviruses.

[45]  S. Kapiga,et al.  Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. , 2016, The New England journal of medicine.

[46]  B. Chi,et al.  Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. , 2016, The New England journal of medicine.

[47]  Ashley J. Mayo,et al.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. , 2016, The New England journal of medicine.

[48]  F. Martinson,et al.  Long-term follow-up of HIV seroconverters in microbicide trials – rationale, study design, and challenges in MTN-015 , 2016, HIV clinical trials.

[49]  James Y. Dai,et al.  Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical Tenofovir , 2016, Antimicrobial Agents and Chemotherapy.

[50]  James Y. Dai,et al.  A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy , 2016, Journal of the International AIDS Society.

[51]  R. Buckheit,et al.  Current and emerging formulation strategies for the effective transdermal delivery of HIV inhibitors. , 2015, Therapeutic delivery.

[52]  Andrew D. Huber,et al.  4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms* , 2014, The Journal of Biological Chemistry.

[53]  L. van Damme,et al.  FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-exposure Prophylaxis , 2014, Journal of acquired immune deficiency syndromes.

[54]  J. Baeten,et al.  Successful Discontinuation of the Placebo Arm and Provision of an Effective HIV Prevention Product After a Positive Interim Efficacy Result: The Partners PrEP Study Experience , 2014, Journal of acquired immune deficiency syndromes.

[55]  Alison L. Drake,et al.  Incident HIV during Pregnancy and Postpartum and Risk of Mother-to-Child HIV Transmission: A Systematic Review and Meta-Analysis , 2014, PLoS medicine.

[56]  L. Mofenson,et al.  Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life , 2014, Journal of acquired immune deficiency syndromes.

[57]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[58]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[59]  J. Piper,et al.  Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy. , 2011, The Journal of infectious diseases.

[60]  L. Mofenson,et al.  Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants , 2011, Antimicrobial Agents and Chemotherapy.

[61]  D. Moodley,et al.  Incident HIV infection in pregnant and lactating women and its effect on mother-to-child transmission in South Africa. , 2011, The Journal of infectious diseases.

[62]  E. Emanuel,et al.  Undue inducement in clinical research in developing countries: is it a worry? , 2005, The Lancet.